These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27738784)

  • 1. Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics.
    Dobrowolski C; Clark EG; Sood MM
    J Thromb Thrombolysis; 2017 Feb; 43(2):241-247. PubMed ID: 27738784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Venous thromboembolic complications in patients with chronic kidney disease: prevalence and features of drug treatment].
    Dzhioeva ON; Orlova AA; Rogozhkina EA; Drapkina OM
    Ter Arkh; 2022 Jan; 94(1):129-134. PubMed ID: 36286928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal function and venous thromboembolic diseases.
    Janus N; Mahé I; Launay-Vacher V; Laroche JP; Deray G
    J Mal Vasc; 2016 Dec; 41(6):389-395. PubMed ID: 28029509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
    Harel Z; Sood MM; Perl J
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):183-92. PubMed ID: 25636144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
    Bauersachs R
    Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts.
    Mahmoodi BK; Gansevoort RT; Næss IA; Lutsey PL; Brækkan SK; Veeger NJ; Brodin EE; Meijer K; Sang Y; Matsushita K; Hallan SI; Hammerstrøm J; Cannegieter SC; Astor BC; Coresh J; Folsom AR; Hansen JB; Cushman M
    Circulation; 2012 Oct; 126(16):1964-71. PubMed ID: 22977129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey.
    Parker K; Choudhuri S; Lewis P; Thachil J; Mitra S
    BMC Nephrol; 2023 Jan; 24(1):9. PubMed ID: 36635661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence.
    Rattazzi M; Villalta S; De Lucchi L; Sponchiado A; Galliazzo S; Faggin E; Pagliara V; Zilli C; Callegari E; Caberlotto L; Puato M; Pauletto P
    Thromb Res; 2017 Dec; 160():32-37. PubMed ID: 29091810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism, factor VIII and chronic kidney disease.
    Cheung KL; Bouchard BA; Cushman M
    Thromb Res; 2018 Oct; 170():10-19. PubMed ID: 30081388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality.
    Königsbrügge O; Lötsch F; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2014 Jul; 134(1):44-9. PubMed ID: 24792954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants.
    Wharin C; Tagalakis V
    Blood Rev; 2014 Jan; 28(1):1-8. PubMed ID: 24360911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
    Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
    Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism.
    Piovella F; Iosub DI
    Thromb Res; 2017 Apr; 152():87-92. PubMed ID: 28017344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding.
    Winkelmayer WC
    Ann Intern Med; 2014 Sep; 161(6):JC10. PubMed ID: 25222410
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidance for the prevention and treatment of cancer-associated venous thromboembolism.
    Khorana AA; Carrier M; Garcia DA; Lee AY
    J Thromb Thrombolysis; 2016 Jan; 41(1):81-91. PubMed ID: 26780740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Black SA; Cohen AT
    Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.